フランス - フランス語 - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

laboratoire glaxosmithkline - salbutamol - suspension - 100 microgrammes - composition pour une dose > salbutamol : 100 microgrammes . sous forme de : sulfate de salbutamol 120,5 microgrammes - bronchodilatateur bêta-2 mimétique à action rapide et de courte durée par voie inhalée (r système respiratoire)

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 1 mg/ml (plus 0.2mg/ml overage);   - solution for inhalation - 2.5mg/2.5ml - active: salbutamol sulfate 1 mg/ml (plus 0.2mg/ml overage)   excipient: sodium chloride sulfuric acid water for injection - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 2 mg/ml (plus 0.4mg/ml overage);   - solution for inhalation - 5mg/2.5ml - active: salbutamol sulfate 2 mg/ml (plus 0.4mg/ml overage)   excipient: sodium chloride sulfuric acid water for injection - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

ベルギー - フランス語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline pharmaceuticals sa-nv - sulfate de salbutamol 120,5 µg/dose - eq. salbutamol 100 µg/dose - suspension pour inhalation en flacon pressurisé - 100 microgrammes/dose - salbutamol 100 µg/dose - salbutamol

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

viatris limited - salbutamol sulfate 120ug equivalent to salbutamol 100 µg;   - aerosol inhaler, metered dose - 100 mcg/dose - active: salbutamol sulfate 120ug equivalent to salbutamol 100 µg   excipient: ethanol norflurane oleic acid - with its fast onset of action, it is particularly suitable for the management and prevention of attack in mild asthma and for the treatment of acute exacerbations in moderate and severe asthma.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 0.6 mg/ml equivalent to 0.5 mg/ml salbutamol;   - solution for injection - 0.5 mg/ml - active: salbutamol sulfate 0.6 mg/ml equivalent to 0.5 mg/ml salbutamol   excipient: sodium chloride sodium hydroxide sulfuric acid water for injection - respiratory. salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. broncodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failing to respond to treatment with salbutamol may signal a need for urgent medical advice or treatment. relief of severe bronchospasm associated with asthma or bronchitis and for the treatment of status asthmaticus.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 1.2 mg/ml equivalent to 1 mg/ml salbutamol;   - solution for injection - 5mg/5ml - active: salbutamol sulfate 1.2 mg/ml equivalent to 1 mg/ml salbutamol   excipient: sodium chloride sodium hydroxide sulfuric acid water for injection - respiratory. salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. broncodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failing to respond to treatment with salbutamol may signal a need for urgent medical advice or treatment. relief of severe bronchospasm associated with asthma or bronchitis and for the treatment of status asthmaticus.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

neutec inhaler ireland limited - ipratropium bromide monohydrate; salbutamol sulfate - nebuliser solution - salbutamol and ipratropium bromide

カナダ - フランス語 - Health Canada

apotex inc - salbutamol (sulfate de salbutamol) - solution - 1mg - salbutamol (sulfate de salbutamol) 1mg - selective beta 2-adrenergic agonists

カナダ - フランス語 - Health Canada

apotex inc - salbutamol (sulfate de salbutamol) - solution - 2mg - salbutamol (sulfate de salbutamol) 2mg - selective beta 2-adrenergic agonists